Q3 EPS Forecast for X4 Pharmaceuticals Increased by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Brookline Capital Management upped their Q3 2025 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, October 27th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($1.42) per share for the quarter, up from their prior estimate of ($1.74). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Capital Management also issued estimates for X4 Pharmaceuticals’ Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($4.30) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($2.09) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at $1.55 EPS.

Several other brokerages also recently issued reports on XFOR. Weiss Ratings reiterated a “sell (e+)” rating on shares of X4 Pharmaceuticals in a report on Wednesday, October 8th. Stifel Nicolaus decreased their price target on X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating for the company in a report on Friday, August 29th. HC Wainwright set a $3.50 target price on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 13th. Finally, Zacks Research upgraded X4 Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, X4 Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

X4 Pharmaceuticals Stock Up 6.7%

Shares of XFOR opened at $3.99 on Thursday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $26.83. The company has a market cap of $45.53 million, a P/E ratio of -0.27 and a beta of 0.54. The company has a debt-to-equity ratio of 19.10, a current ratio of 3.19 and a quick ratio of 3.05. The firm has a 50 day simple moving average of $3.44 and a two-hundred day simple moving average of $3.13.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Friday, August 8th. The company reported ($3.47) EPS for the quarter, beating the consensus estimate of ($4.53) by $1.06. X4 Pharmaceuticals had a negative net margin of 311.15% and a negative return on equity of 375.31%. The firm had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.62 million.

Insider Activity

In other X4 Pharmaceuticals news, Chairman Adam R. Craig bought 86,206 shares of the stock in a transaction on Thursday, October 23rd. The shares were acquired at an average price of $2.90 per share, with a total value of $249,997.40. Following the acquisition, the chairman directly owned 376,087 shares of the company’s stock, valued at $1,090,652.30. The trade was a 29.74% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.37% of the stock is currently owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC increased its holdings in shares of X4 Pharmaceuticals by 112.5% in the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares during the period. Rhumbline Advisers boosted its position in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after buying an additional 9,690 shares during the period. Kingdon Capital Management L.L.C. boosted its holdings in shares of X4 Pharmaceuticals by 41.8% during the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock worth $1,655,000 after purchasing an additional 2,063,000 shares during the period. Pale Fire Capital SE boosted its holdings in shares of X4 Pharmaceuticals by 45.2% during the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after purchasing an additional 633,398 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after purchasing an additional 43,320 shares during the period. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.